CKD-516 + irinotecan

CKD-516 + irinotecan is a **combination regimen** comprising CKD-516—a novel oral small molecule vascular disrupting agent (VDA)—and irinotecan, a topoisomerase I inhibitor. CKD-516 acts by binding to tubulin, disrupting tumor vasculature and thereby promoting necrosis of tumor tissue. Irinotecan, a camptothecin derivative, exerts antitumor activity by inhibiting DNA topoisomerase I, preventing DNA replication and transcription in cancer cells. The combination has been investigated in treatment-refractory metastatic colorectal cancer, demonstrating a manageable safety profile and preliminary antitumor efficacy, with the most common adverse events being gastrointestinal and hematologic. The combination leverages distinct mechanisms to potentially enhance antitumor responses in solid tumors[2][4][5].

Brand names

valecobulin

Other names

CKD-516 + irinotecan